We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ironwood Stock Up, Heart Candidate Gets Fast Track Status
Read MoreHide Full Article
Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) announced that the FDA has granted a fast track designation to its lead pipeline candidate, praliciguat, for the treatment of heart failure with preserved ejection fraction (HFpEF).
Praliciguat (IW-1973), an orally administered soluble guanylate cyclase (sGC) stimulator, is currently being evaluated in a phase II study for the above indication.
The FDA assigns a fast track designation to expedite the development and review process of a candidate, currently under development to treat serious and unmet medical conditions. The fast track status provides more frequent interactions with the regulatory authority for rolling review of the marketing application.
Ironwood plans to enroll (n= 175) patients with HFpEF in the double-blind, placebo-controlled phase II study of praliciguat. While enrolment progresses, the company plans to report top-line results from the study during the second half of 2019.
Shares of Ironwood were up nearly 5% following the news on Thursday. In fact, the stock has rallied 21.4% so far this year compared with the industry’s increase of 0.9%.
Apart from this trial, Ironwood is examining praliciguat for diabetic nephropathy. Top-line outcomes from this program are also expected in the second half of 2019.
Ironwood has another sGC stimulator in its pipeline, IW-1701, which is being developed for the potential treatment of achalasia and sickle cell disease. In July, the FDA granted an orphan drug designation to the candidate for treating sickle cell disease.
We remind investors that Ironwood’s sole marketed drug, Linzess, is indicated for addressing irritable bowel syndrome with constipation and chronic idiopathic constipation. The company co-develops and co-commercializes Linzess and equally shares Linzess’ U.S. collaboration profits/losses as well as development costs with Allergan .
Ironwoord remains on track to complete its bifurcation into two publicly trading entities in the first half 2019. Earlier this May, the company announced its intention of splitting to achieve greater operational efficiency and strategic flexibility.
One of the entities is set to continue with the current name and focus on the company’s three commercial drugs as well as its gastrointestinal pipeline development. While the other one will focus on developing the sGC pipeline for dealing with serious and orphan diseases.
Ironwood Pharmaceuticals, Inc. Price and Consensus
Ironwood currently carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the healthcare sector are BioSpecifics Technologies Corp. and Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BioSpecifics’ earnings estimates have moved 9.1% north for 2018 and 11.7% for 2019 over the past 60 days. The stock has surged 41.2% year to date.
Pacira’s earnings estimates have been revised 104.2% upward for 2018 and 11.5% for 2019 over the past 60 days. The stock has gained 3.7% so far this year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Ironwood Stock Up, Heart Candidate Gets Fast Track Status
Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) announced that the FDA has granted a fast track designation to its lead pipeline candidate, praliciguat, for the treatment of heart failure with preserved ejection fraction (HFpEF).
Praliciguat (IW-1973), an orally administered soluble guanylate cyclase (sGC) stimulator, is currently being evaluated in a phase II study for the above indication.
The FDA assigns a fast track designation to expedite the development and review process of a candidate, currently under development to treat serious and unmet medical conditions. The fast track status provides more frequent interactions with the regulatory authority for rolling review of the marketing application.
Ironwood plans to enroll (n= 175) patients with HFpEF in the double-blind, placebo-controlled phase II study of praliciguat. While enrolment progresses, the company plans to report top-line results from the study during the second half of 2019.
Shares of Ironwood were up nearly 5% following the news on Thursday. In fact, the stock has rallied 21.4% so far this year compared with the industry’s increase of 0.9%.
Apart from this trial, Ironwood is examining praliciguat for diabetic nephropathy. Top-line outcomes from this program are also expected in the second half of 2019.
Ironwood has another sGC stimulator in its pipeline, IW-1701, which is being developed for the potential treatment of achalasia and sickle cell disease. In July, the FDA granted an orphan drug designation to the candidate for treating sickle cell disease.
We remind investors that Ironwood’s sole marketed drug, Linzess, is indicated for addressing irritable bowel syndrome with constipation and chronic idiopathic constipation. The company co-develops and co-commercializes Linzess and equally shares Linzess’ U.S. collaboration profits/losses as well as development costs with Allergan .
Ironwoord remains on track to complete its bifurcation into two publicly trading entities in the first half 2019. Earlier this May, the company announced its intention of splitting to achieve greater operational efficiency and strategic flexibility.
One of the entities is set to continue with the current name and focus on the company’s three commercial drugs as well as its gastrointestinal pipeline development. While the other one will focus on developing the sGC pipeline for dealing with serious and orphan diseases.
Ironwood Pharmaceuticals, Inc. Price and Consensus
Ironwood Pharmaceuticals, Inc. Price and Consensus | Ironwood Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Ironwood currently carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the healthcare sector are BioSpecifics Technologies Corp. and Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BioSpecifics’ earnings estimates have moved 9.1% north for 2018 and 11.7% for 2019 over the past 60 days. The stock has surged 41.2% year to date.
Pacira’s earnings estimates have been revised 104.2% upward for 2018 and 11.5% for 2019 over the past 60 days. The stock has gained 3.7% so far this year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>